Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05256316 · ClinicalTrials.gov registry record
Risks of Bacterial and Fungal Superinfection in Patients With COVID-19
A clinical trial, sponsored by The University of Queensland.
- Completed
- Registry status
- 790
- Enrollment target
NCT05256316 is a clinical trial that has completed, run by The University of Queensland. The registered enrollment target is 790 participants.
The verdict
NCT05256316 has completed, sponsored by The University of Queensland.
- COMPLETED
- Registry status
- 790 participants
- Enrollment target
Study Summary
Infection with bacteria or fungi can be deadly. Often, these types of infections can lead to an increase in the severity of illness requiring intensive care unit (ICU) admission, prolonged duration of treatment and further risks associated with additional infections and superinfections. These are also called hospital acquired secondary infections. Patients who contract COVID-19 and require an ICU admission are at increased risk of contracting these secondary infections, and receive certain medications that can lower your body's immune response. In COVID-19 patients who require these treatments, it is unclear what affect these medications can have on developing an additional infection as well as the rate of recovery/survival. This study is evaluating the effect these medications have on the development of secondary infections and rate of survival of COVID-19 patients that have been admitted to ICUs.
Interventions
- OTHER Previously admitted COVID-19 patients in intensive care units
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 790 participants |
| Start Date | 2022-02-14 |
| Est. Completion | 2022-12-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05256316
The ClinicalTrials.gov registry entry for NCT05256316 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 790 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Queensland, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Previously admitted COVID-19 patients in intensive care units is the first listed.
NCT05256316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05256316 about?
NCT05256316 is a clinical study titled "Risks of Bacterial and Fungal Superinfection in Patients With COVID-19". Infection with bacteria or fungi can be deadly. Often, these types of infections can lead to an increase in the severity of illness requiring intensive care unit (ICU) admission, prolonged duration of treatment and further risks associated with additional infections and superinfections. These are al...
What is the current status of trial NCT05256316?
This trial is currently completed. The enrollment target is 790 participants. The study started on 2022-02-14. Estimated completion is 2022-12-04.
What interventions are being tested in trial NCT05256316?
The interventions under investigation include: Previously admitted COVID-19 patients in intensive care units (OTHER).
Who is sponsoring clinical trial NCT05256316?
This trial is sponsored by The University of Queensland, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.